相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Complement as a regulator of adaptive immunity
Justin Killick et al.
SEMINARS IN IMMUNOPATHOLOGY (2018)
CD59: a promising target for tumor immunotherapy
Ronghua Zhang et al.
FUTURE ONCOLOGY (2018)
Targeting complement-mediated immunoregulation for cancer immunotherapy
Martin Kolev et al.
SEMINARS IN IMMUNOLOGY (2018)
Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy
Aurelie Durgeau et al.
FRONTIERS IN IMMUNOLOGY (2018)
Unraveling the Role of Angiogenesis in Cancer Ecosystems
Iratxe Zuazo-Gaztelu et al.
FRONTIERS IN ONCOLOGY (2018)
Beyond the Role of CD55 as a Complement Component
So Hee Dho et al.
IMMUNE NETWORK (2018)
The complement system in cancer: Ambivalence between tumour destruction and promotion
Srinivas Mamidi et al.
IMMUNOBIOLOGY (2017)
A novel hemolytic complement-sufficient NSG mouse model supports studies of complement-mediated antitumor activity in vivo
Mohit K. Verma et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2017)
Antibody Distance from the Cell Membrane Regulates Antibody Effector Mechanisms
Kirstie L. S. Cleary et al.
JOURNAL OF IMMUNOLOGY (2017)
Role of tumor microenvironment in tumorigenesis
Maonan Wang et al.
JOURNAL OF CANCER (2017)
Therapeutic Antibodies: What Have we Learnt from Targeting CD20 and Where Are We Going?
Michael J. E. Marshall et al.
FRONTIERS IN IMMUNOLOGY (2017)
Obinutuzumab: what is there to learn from clinical trials?
Guillaume Cartron et al.
BLOOD (2017)
Production of complement components by cells of the immune system
R. Lubbers et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2017)
State of the art in anti-cancer mAbs
S. M. Chiavenna et al.
JOURNAL OF BIOMEDICAL SCIENCE (2017)
A new approach for the treatment of CLL using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticles
Sara Capolla et al.
NANO RESEARCH (2016)
New perspectives on complement mediated immunotherapy
Grzegorz Stasilojc et al.
CANCER TREATMENT REVIEWS (2016)
Cytotoxic activity against human neuroblastoma and melanoma cells mediated by IgM antibodies derived from peripheral blood of healthy donors
Satish Kumar Devarapu et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions
Erika M. Cook et al.
JOURNAL OF IMMUNOLOGY (2016)
Real-time analysis of the detailed sequence of cellular events in mAb-mediated complement-dependent cytotoxicity of B-cell lines and of chronic lymphocytic leukemia B-cells
Margaret A. Lindorfer et al.
MOLECULAR IMMUNOLOGY (2016)
Cytotoxic mechanisms of immunotherapy: Harnessing complement in the action of anti-tumor monoclonal antibodies
Ronald P. Taylor et al.
SEMINARS IN IMMUNOLOGY (2016)
C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation
Roberta Bulla et al.
NATURE COMMUNICATIONS (2016)
The High Prevalence of Functional Complement Defects Induced by Chemotherapy
Mischa P. Keizer et al.
FRONTIERS IN IMMUNOLOGY (2016)
Fc gamma receptors: glycobiology and therapeutic prospects
Jerrard M. Hayes et al.
JOURNAL OF INFLAMMATION RESEARCH (2016)
Complement Is a Central Mediator of Radiotherapy-Induced Tumor-Specific Immunity and Clinical Response
Laura Surace et al.
IMMUNITY (2015)
Complement activation in Glioblastoma Multiforme pathophysiology: Evidence from serum levels and presence of complement activation products in tumor tissue
T. A. M. Bouwens et al.
JOURNAL OF NEUROIMMUNOLOGY (2015)
Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab
I. S. Nijhof et al.
LEUKEMIA (2015)
Natural and adaptive IgM antibodies in the recognition of tumor-associated antigens of breast cancer
Mariana Diaz-Zaagoza et al.
ONCOLOGY REPORTS (2015)
Complement system part I - molecular mechanisms of activation and regulation
Nicolas S. Merle et al.
FRONTIERS IN IMMUNOLOGY (2015)
Bispecific antibodies targeting tumor-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherapy in mice
P. Macor et al.
LEUKEMIA (2015)
Complement C5a Receptor Facilitates Cancer Metastasis by Altering T-Cell Responses in the Metastatic Niche
Surya Kumari Vadrevu et al.
CANCER RESEARCH (2014)
Complement in Antibody-Based Tumor Therapy
Stefanie Derer et al.
CRITICAL REVIEWS IN IMMUNOLOGY (2014)
The extracellular matrix modulates the hallmarks of cancer
Michael W. Pickup et al.
EMBO REPORTS (2014)
Mortalin/GRP75 Binds to Complement C9 and Plays a Role in Resistance to Complement-dependent Cytotoxicity
Moran Saar Ray et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Cancer cells release anaphylatoxin C5a from C5 by serine protease to enhance invasiveness
Hidetoshi Nitta et al.
ONCOLOGY REPORTS (2014)
Complement Is Activated by IgG Hexamers Assembled at the Cell Surface
Christoph A. Diebolder et al.
SCIENCE (2014)
Complement-Dependent Modulation of Antitumor Immunity following Radiation Therapy
Michelle Elvington et al.
CELL REPORTS (2014)
Autocrine Effects of Tumor-Derived Complement
Min Soon Cho et al.
CELL REPORTS (2014)
The complement membrane attack complex triggers intracellular Ca2+ fluxes leading to NLRP3 inflammasome activation
Kathy Triantafilou et al.
JOURNAL OF CELL SCIENCE (2013)
Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab
Srinivas Mamidi et al.
MOLECULAR ONCOLOGY (2013)
New Potential Therapeutic Approach for the Treatment of B-Cell Malignancies Using Chlorambucil/Hydroxychloroquine- Loaded Anti-CD20 Nanoparticles
Nelly Mezzaroba et al.
PLOS ONE (2013)
Early onset and enhanced growth of autochthonous mammary carcinomas in C3-deficient Her2/neu transgenic mice
Silvio Bandini et al.
ONCOIMMUNOLOGY (2013)
Anaphylatoxin C5a Creates a Favorable Microenvironment for Lung Cancer Progression
Leticia Corrales et al.
JOURNAL OF IMMUNOLOGY (2012)
Exhaustion of Cytotoxic Effector Systems May Limit Monoclonal Antibody-Based Immunotherapy in Cancer Patients
Frank J. Beurskens et al.
JOURNAL OF IMMUNOLOGY (2012)
The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents
Dietmar W. Siemann
CANCER TREATMENT REVIEWS (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Enhancing the action of rituximab by adding fresh frozen plasma for the treatment of fludarabine refractory chronic lymphocytic leukemia
Wei Xu et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
Michel de Weers et al.
JOURNAL OF IMMUNOLOGY (2011)
Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and Alemtuzumab
Luca Bologna et al.
JOURNAL OF IMMUNOLOGY (2011)
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
Robert D. Schreiber et al.
SCIENCE (2011)
CD46 Expression is an Unfavorable Prognostic Factor in Breast Cancer Cases
Adam Maciejczyk et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2011)
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
Ekkehard Moessner et al.
BLOOD (2010)
In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma
K. El-Sahwi et al.
BRITISH JOURNAL OF CANCER (2010)
Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value
A. Michlmayr et al.
BRITISH JOURNAL OF CANCER (2010)
Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo
Yi-Fan Hsu et al.
MOLECULAR CANCER (2010)
Enhancing the Action of Rituximab in Chronic Lymphocytic Leukemia by Adding Fresh Frozen Plasma Complement/Rituximab Interactions & Clinical Results in Refractory CLL
Abraham Klepfish et al.
CONTEMPORARY CHALLENGES IN AUTOIMMUNITY (2009)
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
Robert Pirker et al.
LANCET (2009)
Natural antibodies and cancer
H. Peter Vollmers et al.
NEW BIOTECHNOLOGY (2009)
Neutralization of complement regulatory proteins CD55 and CD59 augments therapeutic effect of herceptin against lung carcinoma cells
Wei-Peng Zhao et al.
ONCOLOGY REPORTS (2009)
Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies
Michael Dechant et al.
CANCER RESEARCH (2008)
Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab
Clive S. Zent et al.
LEUKEMIA RESEARCH (2008)
Modulation of the antitumor immune response by complement
Maciej M. Markiewski et al.
NATURE IMMUNOLOGY (2008)
In Vivo Biodistribution and Lifetime Analysis of Cy5.5-Conjugated Rituximab in Mice Bearing Lymphoid Tumor Xenograft Using Time-Domain Near-Infrared Optical Imaging
Steania Biffi et al.
MOLECULAR IMAGING (2008)
In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab
Paolo Macor et al.
CANCER RESEARCH (2007)
Live cell imaging of outward and inward vesiculation induced by the complement C5b-9 complex
Oren Moskovich et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Complement as effector system in cancer immunotherapy
Paolo Macor et al.
IMMUNOLOGY LETTERS (2007)
Complement activated by chimeric anti-folate receptor antibodies is an efficient effector system to control ovarian carcinoma
P Macor et al.
CANCER RESEARCH (2006)
Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro
J Hodoniczky et al.
BIOTECHNOLOGY PROGRESS (2005)
Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59
F Ziller et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2005)
Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts
MS Cragg et al.
BLOOD (2003)
CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59
J Golay et al.
BLOOD (2001)
High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR
RL Shields et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Engineered antibodies with increased activity to recruit complement
EE Idusogie et al.
JOURNAL OF IMMUNOLOGY (2001)
分享论文
